SecBot SecBot
8-K ·Filed Aug 6, 2026

AGEN

AGENUS INC
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001193125-26-336780
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the upcoming corporate strategy webcast on September 10, 2026, for details on ROBBIN trial execution and potential updates on the BATTMAN termination fallout. The stock's reaction will depend on investor sentiment regarding the trade-off between the promising ROBBIN opportunity and the loss of the BATTMAN data readout.

DirectionNeutral
Confidencemedium
Horizonweeks

Drugs in focus

AGEN drug pipeline →

botensilimab

◆ Mixed Named in this 8-K
Impact
Phase
Phase 3
Time to market
At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
Next catalyst
None dated

What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.49
T+0 close · Aug 6, 2026 · via day close
Latest settled
−8.68%
T+60 · $6.84
Vs SPY
−7.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $7.49entry
  2. T+1 · 3mo ago −7.08%α −7.69% · $6.96
  3. T+5 · 3mo ago −6.54%α −7.75% · $7.00
  4. T+20 · 3mo ago +10.01%α +9.41% · $8.24
  5. T+60 · 18d ago −8.68%α −7.01% · $6.84
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Agenus reported Q2 2026 total revenue of $34.5M (up 34% YoY from $25.7M), driven by $6.4M in pre-commercial BOT+BAL product revenue and $28.1M in non-cash royalty revenue. The company highlighted its oversubscribed $85M private placement to fund the Phase 3 ROBBIN trial, but also disclosed the termination of the BATTMAN Phase 3 study due to funding prioritization. The filing is neutral as the revenue beat is largely non-cash royalty revenue, and the strategic pivot to ROBBIN comes at the cost of the BATTMAN trial, creating offsetting signals for a pre-revenue biotech.

Key Financial Metrics

Revenue
$34.5M
est $34.0M · +1.5% · +34.2% YoY

Key Facts

  • Total revenue for Q2 2026 was $34.5M, up from $25.7M in Q2 2025.
  • Pre-commercial BOT+BAL product revenue was $6.4M in Q2 2026, up from $4.6M in Q1 2026.
  • Non-cash royalty revenue was $28.1M in Q2 2026, up from $24.8M in Q2 2025.
  • Agenus completed an oversubscribed $85M private placement in July 2026 to support the ROBBIN trial.
  • Agenus discontinued funding for the Phase 3 BATTMAN trial, leading to its termination by CCTG.
  • Cash and cash equivalents were $35.0M as of March 31, 2026, with an additional $11.7M in net proceeds from ATM sales received post-quarter-end.
  • The company expects the upfront proceeds from the private placement to support operations through Q3 2027.

Financial Impact

Revenue of $34.5M in Q2 2026, with $28.1M being non-cash royalty revenue. The $85M private placement provides a cash runway through Q3 2027.

revenuecash

Risk Factors

  • Termination of the BATTMAN Phase 3 trial removes a key pipeline catalyst and may raise questions about clinical strategy.
  • Reliance on non-cash royalty revenue for the majority of reported revenue does not provide actual cash flow.
  • Execution risk for the large, global Phase 3 ROBBIN trial, which is still in the initiation phase.
  • Potential shareholder dilution from the exercise of milestone-aligned warrants, which could provide up to $255M in additional proceeds.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-336780
Document: agen-ex99_1.htm0001193125-26-336780
Document: 0001193125-26-336780-index-headers.html0001193125-26-336780
Document: 0001193125-26-336780-index.html0001193125-26-336780
Document: 0001193125-26-336780.txt0001193125-26-336780
8-K Data (Synthetic)0001193125-26-336780

Track record

12 reports on AGEN

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
  4. Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
  6. Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
  7. Aug 6, 202614w ago 8-K Neutral 5/10 Viewing Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
  8. Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
  9. Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
  10. May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (10h 24m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026